Steffan Crausaz

Learn More
Pharmaceutical expenditure has increased rapidly across many Organisation for Economic Cooperation and Development (OECD) countries over the past three decades. This growth is an increasing concern for governments and other third-party payers seeking to provide equitable and comprehensive healthcare within sustainable budgets. In order to create headroom(More)
Publicly funded cancer medicines listed on the New Zealand Pharmaceutical Schedule were compared with those listed on the Australian Pharmaceutical Benefits Scheme. To quantify the health gains offered by the cancer medicines funded in Australia but not in New Zealand, clinical trial data reporting median progression-free survival (PFS) and overall survival(More)
67 Meeting the high and increasing price of medicines for rare disorders is an ongoing dilemma for patients, insurers and governments worldwide. In New Zealand, the difficulty has been highlighted by lobbyists campaigning for funding eculizumab for paroxysmal nocturnal haemoglobinuria and for enzyme replacement therapies including alglucosidase alfa for(More)
Dr David Hamilton (http://www.nzma.org.nz/journal/118-1227/1774) accurately describes the clinical benefits of temozolomide and PHARMAC’s consideration of funding; and how this relates to what price to pay to prolong survival in incurable illnesses. We update progress with the funding of temozolomide, and agree there are dilemmas around the funding of(More)
  • 1